UNSPSC 51151550: Rivastigmine hydrogentartrate

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C14H22N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9IY2357JPE, chemically known as carbamic acid, n-ethyl-n-methyl-, 3-((1s)-1-(dimethylamino)ethyl)phenyl ester, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as rivastigmine hydrogentartrate, which bears US NIH Compound Identifier 77990.

European Medicines Agency schedules rivastigmine hydrogentartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10345MIG. Most nations, for tariff purposes, schedule rivastigmine hydrogentartrate under HS 29242995. SMILES: CCN(C)C(=O)OC1CCCC(C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51151550 Rivastigmine hydrogentartrate is a Commodity code that shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code describes a specific pharmaceutical compound, but the two recent opportunities posted under it procure naloxone and safe drug deactivation systems (Seminole County, Florida) and solicit vendor capabilities for direct-to-manufacturer prescription programs (Texas Health and Human Services Commission). Neither opportunity involves rivastigmine acquisition. State and local governments buying pharmaceutical products appear to be using this code as a catch-all for healthcare procurement without regard to the specific active ingredient or therapeutic class the code nominally covers. The issuing bodies—a county health authority and a state health agency—reflect the typical pattern of standalone jurisdictions managing their own pharmaceutical purchases rather than consolidated statewide cooperative vehicles.

Geographic activity centers on Florida and Texas based on the two most recent postings. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 with a response deadline of July 26, 2023 (note: the due date in the source appears to contain a date discrepancy) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and an initial two-year contract term with one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013) on April 3, 2026 to gather vendor capabilities for implementing a direct-to-manufacturer pharmacy program that would bypass traditional pharmacy benefit managers. The naloxone opportunity includes FEMA funding and standard compliance requirements; the Texas RFI functions as early market research rather than a competitive award. The code shows minimal recent activity mapped to its stated pharmaceutical scope, signaling either administrative coding errors or a need to review whether rivastigmine procurement is actually occurring under different UNSPSC classifications.